Bioprinting, a method that uses 3D printing techniques to synthesize living tissues utilizing bioink products, could rapidly accelerate the timeline for testing new pharmaceuticals by allowing new products to be tested on synthetic human tissues rather than on animal subjects. This would allow greater accuracy of test results and a faster speed to market. Bioprinting is used to develop manufactured 3D living tissue, bone, blood vessels and potentially whole organs for use in medical procedures, training, and testing. With many different manufacturers and academic researchers developing bioink products, there is a lack of standardization for bioink printers such as nozzle temperature, printing time, dispensing pressure, printing speed, and nozzle diameter; all of which directly influence the precision and accuracy of bioink deposition. Standards in this area will allow product developers to more easily reproduce test results and control product quality.

ASME plans to collaborate under the guidance of the Standards Coordinating Body (SCB) with ASTM and IEEE, who are developing complementary but distinct standards.

Current status
A Bioprinters Standards Committee is being formed to develop a bioprinter hardware standard on extrusion bioprinters. Initial work is being done to provide guidelines for extrusion bioprinting calibration of devices, operations, compatibility, and interoperability of these components to best print ex vivo “outside an organism” tissue results. 
Meetings and Events
Bioprinters Hardware Standards Committee - meets every 1-2 months via teleconference.
ASME Advanced Manufacturing (AM) Medical on May 27 – 28, 2020 in Minneapolis, MN.

Staff Contact
If you’re interested in learning more or participating in these activities, please contact Luis Pulgarin.

You are now leaving